KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short-term Investments: 2009-2024

Historic Short-term Investments for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Dec 2024 value amounting to $20.6 million.

  • Rigel Pharmaceuticals' Short-term Investments rose 840.45% to $88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.6 million, marking a year-over-year increase of 840.45%. This contributed to the annual value of $20.6 million for FY2024, which is 14.79% down from last year.
  • Per Rigel Pharmaceuticals' latest filing, its Short-term Investments stood at $20.6 million for FY2024, which was down 14.79% from $24.1 million recorded in FY2023.
  • Rigel Pharmaceuticals' 5-year Short-term Investments high stood at $106.1 million for FY2021, and its period low was $20.6 million during FY2024.
  • Over the past 3 years, Rigel Pharmaceuticals' median Short-term Investments value was $24.1 million (recorded in 2023), while the average stood at $26.2 million.
  • Per our database at Business Quant, Rigel Pharmaceuticals' Short-term Investments spiked by 293.55% in 2021 and then crashed by 68.19% in 2022.
  • Yearly analysis of 5 years shows Rigel Pharmaceuticals' Short-term Investments stood at $27.0 million in 2020, then skyrocketed by 293.55% to $106.1 million in 2021, then tumbled by 68.19% to $33.7 million in 2022, then decreased by 28.45% to $24.1 million in 2023, then declined by 14.79% to $20.6 million in 2024.